Ibsrela
Irritable Bowel Syndrome
Treatment
2 Active Studies for Ibsrela
Treatment for
Irritable Bowel Syndrome
What is Ibsrela
Tenapanor
The Generic name of this drug
Treatment Summary
Tenapanor is a new medication used to treat constipation-predominant irritable bowel syndrome (IBS-C). It was designed and developed in 2012 and approved by the FDA in 2019. It works by blocking the activity of the sodium/hydrogen exchanger isoform 3 (NHE3) transporter. This medication is the only one of its kind and provides a new option for treating IBS-C.
Ibsrela
is the brand name
Ibsrela Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Ibsrela
Tenapanor
2019
1
Effectiveness
How Ibsrela Affects Patients
Tenapanor stops your body from absorbing sodium, which leads to an increase in water in your intestines. This reduces the time it takes for food to move through and makes stools softer.
How Ibsrela works in the body
Tenapanor is a medicine that stops a protein in the gut from working properly. This protein helps to balance salt and water levels in the gut. By blocking this protein, Tenapanor causes salt and water to be retained in the intestine. This leads to softer stool. Tenapanor might also help to reduce the amount of phosphorus absorbed from food, but it is not yet known how it does this.
When to interrupt dosage
The proposed amount of Ibsrela is dependent on the diagnosed condition. The dosage fluctuates as per the mode of delivery featured in the table beneath.
Condition
Dosage
Administration
Irritable Bowel Syndrome
, 53.2 mg, 50.0 mg
Tablet - Oral, , Tablet, Oral
Warnings
Ibsrela Contraindications
Condition
Risk Level
Notes
Mechanical Intestinal Obstruction
Do Not Combine
Pulse Frequency
Do Not Combine
There are 4 known major drug interactions with Ibsrela.
Common Ibsrela Drug Interactions
Drug Name
Risk Level
Description
Asunaprevir
Moderate
The serum concentration of Asunaprevir can be decreased when it is combined with Tenapanor.
Atorvastatin
Moderate
The serum concentration of Atorvastatin can be decreased when it is combined with Tenapanor.
Fexofenadine
Moderate
The serum concentration of Fexofenadine can be decreased when it is combined with Tenapanor.
Pitavastatin
Moderate
The serum concentration of Pitavastatin can be decreased when it is combined with Tenapanor.
Ibsrela Toxicity & Overdose Risk
If a person overdoses on tenapanor, they may experience diarrhea and dehydration. There is no known antidote or treatment for an overdose of tenapanor.
Ibsrela Novel Uses: Which Conditions Have a Clinical Trial Featuring Ibsrela?
A quartet of active trials are assessing the potential of Ibsrela for addressing Constipation-predominant Irritable Bowel Syndrome (IBS-C).
Condition
Clinical Trials
Trial Phases
Irritable Bowel Syndrome
3 Actively Recruiting
Phase 2, Phase 3
Ibsrela Reviews: What are patients saying about Ibsrela?
5
Patient Review
4/19/2022
Ibsrela for Irritable Bowel Syndrome with Constipation
5
Patient Review
5/12/2022
Ibsrela for Irritable Bowel Syndrome with Constipation
3
Patient Review
11/6/2022
Ibsrela for Irritable Bowel Syndrome with Constipation
Patient Q&A Section about ibsrela
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Is Ibsrela available?
"Ibsrela is designed to treat irritable bowel syndrome with constipation (IBS-C) in adults. The medication comes in the form of 50mg tablets which are packaged in 60-count bottles."
Answered by AI
Is Ibsrela available in the US?
"Ardelyx is a pharmaceutical company whose first approved product, IBSRELA (tenapanor), is available in the United States."
Answered by AI
Is Ibsrela FDA approved?
"The FDA has approved a new drug, tenapanor, for the treatment of constipation predominant IBS (IBS-C). The drug works by inhibiting the sodium hydrogen exchanger 3 (NHE3) in the gut, which should help to relieve constipation symptoms."
Answered by AI